Johnson & Johnson (JNJ) Position Lessened by Chesley Taft & Associates LLC

Share on StockTwits

Chesley Taft & Associates LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 203,610 shares of the company’s stock after selling 116 shares during the quarter. Johnson & Johnson comprises about 2.5% of Chesley Taft & Associates LLC’s holdings, making the stock its 5th largest position. Chesley Taft & Associates LLC’s holdings in Johnson & Johnson were worth $26,276,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Selective Wealth Management purchased a new stake in Johnson & Johnson in the 3rd quarter valued at approximately $105,000. Fusion Family Wealth LLC boosted its holdings in Johnson & Johnson by 621.4% in the 2nd quarter. Fusion Family Wealth LLC now owns 1,010 shares of the company’s stock valued at $123,000 after purchasing an additional 870 shares in the last quarter. Ifrah Financial Services Inc. purchased a new stake in Johnson & Johnson in the 3rd quarter valued at approximately $203,000. Exane Asset Management purchased a new stake in Johnson & Johnson in the 2nd quarter valued at approximately $206,000. Finally, Peak Capital Management LLC purchased a new stake in Johnson & Johnson in the 2nd quarter valued at approximately $207,000. 66.43% of the stock is currently owned by hedge funds and other institutional investors.

JNJ stock opened at $138.10 on Friday. Johnson & Johnson has a 12-month low of $118.62 and a 12-month high of $148.99. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.47 and a quick ratio of 1.20. The company has a market cap of $371.42 billion, a PE ratio of 16.88, a P/E/G ratio of 2.12 and a beta of 0.68.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, January 22nd. The company reported $1.97 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.95 by $0.02. Johnson & Johnson had a net margin of 18.75% and a return on equity of 35.63%. The company had revenue of $20.39 billion during the quarter, compared to the consensus estimate of $20.27 billion. During the same period last year, the firm earned $1.74 EPS. The company’s revenue for the quarter was up 1.0% on a year-over-year basis. On average, analysts forecast that Johnson & Johnson will post 8.57 earnings per share for the current year.

Johnson & Johnson announced that its board has initiated a share buyback plan on Monday, December 17th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the company to repurchase up to 1.5% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its shares are undervalued.

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 12th. Stockholders of record on Tuesday, February 26th were given a dividend of $0.90 per share. The ex-dividend date of this dividend was Monday, February 25th. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.61%. Johnson & Johnson’s payout ratio is 44.01%.

JNJ has been the topic of a number of analyst reports. ValuEngine raised Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Thursday, December 13th. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $164.00 price objective on the stock in a report on Wednesday, December 12th. Morgan Stanley lowered their price objective on Johnson & Johnson from $153.00 to $130.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 2nd. Barclays reaffirmed an “equal weight” rating and issued a $135.00 price objective (down previously from $137.00) on shares of Johnson & Johnson in a report on Wednesday, January 23rd. Finally, Citigroup lowered their price objective on Johnson & Johnson from $148.00 to $139.00 and set a “neutral” rating on the stock in a report on Wednesday, January 2nd. Two analysts have rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the stock. Johnson & Johnson presently has a consensus rating of “Hold” and a consensus price target of $142.81.

COPYRIGHT VIOLATION NOTICE: “Johnson & Johnson (JNJ) Position Lessened by Chesley Taft & Associates LLC” was originally published by Zolmax and is the sole property of of Zolmax. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://zolmax.com/investing/johnson-johnson-jnj-position-lessened-by-chesley-taft-associates-llc/2981402.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: Trading Penny Stocks

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Albireo Pharma Inc  Expected to Announce Earnings of -$1.44 Per Share
Albireo Pharma Inc Expected to Announce Earnings of -$1.44 Per Share
Dynex Capital Inc  Plans Monthly Dividend of $0.18
Dynex Capital Inc Plans Monthly Dividend of $0.18
Insider Buying: Ipsidy Inc  CFO Acquires $25,000.00 in Stock
Insider Buying: Ipsidy Inc CFO Acquires $25,000.00 in Stock
Kenneth Michael Dedeluk Sells 5,000 Shares of Computer Modelling Group Ltd.  Stock
Kenneth Michael Dedeluk Sells 5,000 Shares of Computer Modelling Group Ltd. Stock
Tabula Rasa HealthCare Inc  Director Sells $51,520.00 in Stock
Tabula Rasa HealthCare Inc Director Sells $51,520.00 in Stock
Insider Buying: Immunomedics, Inc.  Insider Purchases $66,750.00 in Stock
Insider Buying: Immunomedics, Inc. Insider Purchases $66,750.00 in Stock


 
© 2006-2019 Zolmax.